Harvard Bioscience (HBIO) Profit After Tax (2010 - 2026)

Harvard Bioscience (HBIO) has reported Profit After Tax for 17 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 93.2% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$9.8 million (up 83.15% YoY), while the FY2025 annual figure was -$56.7 million, down 357.07% from the prior year.
• Profit After Tax slipped to -$3.4 million in Q1 2026 per HBIO's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $2.4 million in Q2 2022 and bottomed at -$50.3 million in Q1 2025.
• Historically, Profit After Tax has averaged -$5.0 million across 5 years, with a median of -$2.3 million in 2025.
• Annual changes were most pronounced in 2022 — Profit After Tax surged 693.9% — and 2025, when it slumped 15916.67%.
• Harvard Bioscience's Profit After Tax stood at -$1.7 million in 2022, then slipped by 9.12% to -$1.8 million in 2023, then jumped by 100.99% to $18000.0 in 2024, then plunged by 15916.67% to -$2.8 million in 2025, then fell by 20.27% to -$3.4 million in 2026.
• Business Quant data shows HBIO's Profit After Tax at -$3.4 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.2 million in Q3 2025.